MLEC

ANALYST NOTE: MLEC (Moolec Science S.A.) Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• State: Actionable (Forming Coil)
• Conservative Entry: Not yet triggered (awaiting confirmed breakout above the coil high).
• Aggressive/Pre-Breakout Entry: Not applicable for conservative sizing; current price action is a "watch" zone.
• Breakout Level: Not yet established (requires price to close above the coil resistance).
• Current Price: $8.04.
• Extension: Not applicable (price is within the coil structure, not extended above it).
• ATR Context: Current ATR is 28.7% (Extreme). This indicates severe volatility and high risk of whipsaw. The ATR at breakout is not yet recorded.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Macro Context: There is no named secular thesis attached to this name as of 2026-06-13. The investment case is not driven by a broad macro theme (e.g., "The Great Protein Shift" or "Regulatory Breakthrough") but is strictly a function of the technical setup quality combined with the specific operational milestones recorded by management.

3. Business Analysis

• Company Profile: Moolec Science S.A. is a biotechnology firm specializing in "Molecular Farming," utilizing plant-grown animal proteins (specifically soybeans and peas) to produce alternative proteins.
• Core Product & Traction:
• Glaso: The company is commercializing Glaso, a science-based ingredient. As of the 2024-10-02 earnings transcript, Moolec had contracted 600 acres with key growers to produce Glaso seeds for crushing.
• Offtake Agreements: Management confirmed an offtake agreement with a "leading global CPG company" (E2).
• Applications: Glaso is targeted for dietary supplements, nutritional beverages, infant formulas, animal health, and pet food (E5).
• Revenue Expectations: Management expected Glaso to contribute approximately 15% of total revenue in fiscal year 2025 (E6). They projected Glaso would become a more significant revenue driver in fiscal years 2026 and 2027 (E4).
• Yield Data: Management cited expected yields of ~1,400 tons per acre, targeting 50-60 tons of GLA production for the first year (E7).
• Operational Status (as of 2026-06-13):
• US Expansion: Field trials for "Piggy Sooy" (likely a specific strain or product line) commenced in Ohio, Missouri, and Iowa to support US FDA approvals (E8).
• Financial Restructuring (Bioceres Context): A critical structural change occurred in the group's history. As of the 2025-12-29 filing, the group derecognized Bioceres S.A. and Bioceres LLC following their default and subsequent voluntary bankruptcy proceedings initiated in December 2025. This resulted in an approximate gain of $91.0 million related to the loss of control of Bioceres S.A. (E13).
• Current Financials: The financial spine indicates a forward consensus EPS of -36 for FY1 and a projected positive EPS of 6 for FY2 (E18). The company is transitioning from a loss-making phase to a projected profitable phase.

4. Archetype and Conviction

• Archetype: Growth Leader (with elements of a Margin Inflector).
• *Rationale:* The company is moving from R&D/early commercialization (2024) to a phase of scaling revenue (2025-2026) and achieving profitability (FY2 projection). The derecognition of the distressed Bioceres entity has likely cleaned up the balance sheet, allowing the core Moolec business to be valued on its own growth trajectory.
• Valuation Context: The financial spine shows a transition from negative EPS (-36) to positive EPS (6). This suggests the market is pricing in a turnaround to profitability.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro tailwinds).
• Evidence Quality: High (Specific management guidance on acreage, yields, and offtake exists).
• Structural Quality: Moderate. The setup is "Forming," meaning the risk/reward is favorable but not yet confirmed.
• Rerating Potential: High, contingent on the successful scaling of Glaso revenue as management expects (15% of FY25 revenue, growing thereafter).
• Volatility Warning: The current ATR of 28.7% is Extreme. In the StoryStocks canon, extreme ATR (>8%) correlates with the highest historical severe-loser rate. This suggests the $8.04 price is highly unstable. A forming coil in an extreme ATR environment requires significantly wider stops or smaller position sizes to survive the noise.

5. Invalidations, Strengths, and Gaps

• Invalidation Triggers:
• Fundamental: Failure to meet the Glaso revenue targets (e.g., if FY25 revenue contribution is significantly below the 15% guidance) or delays in US FDA approvals for the Piggy Sooy trials.
• Corporate: Any new distress signals in the remaining group entities or failure to execute the FY2 profitability projection.
• Strengthening Factors:
• A confirmed breakout above the coil resistance with volume.
• Management reaffirming or raising the Glaso revenue guidance for FY26/27.
• Successful completion of US FDA approvals for the new product lines.
• Evidence Gaps:
• Current Revenue Run-rate: While FY25 guidance is given, the actual realized revenue for the first half of 2026 is not explicitly detailed in the provided snippets, only the forward consensus EPS.
• Post-Bankruptcy Integration: The specific impact of the Bioceres bankruptcy on Moolec's operational cash flow or supply chain is not detailed beyond the accounting gain.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Management guidance for 15% Glaso revenue contribution in FY25; confirmed offtake agreement with global CPG; successful derecognition of distressed Bioceres entity generating $91M gain; forward consensus EPS turning positive in FY2. Key risks: Extreme ATR of 28.7% indicating severe volatility and whipsaw risk; setup is only "forming" with no confirmed breakout; reliance on unproven US FDA approvals for new product lines; potential execution risk in scaling 600-acre planting program. Sizing hint: Minimal position size due to extreme volatility and unconfirmed breakout; treat as a high-risk tactical play only. Expected horizon: 3 to 6 months for a potential breakout or invalidation.